Navigation Links
Tianyin Reports Record Fiscal 2010 Financial Results
Date:9/29/2010

modernized traditional Chinese medicines, branded generics and other pharmaceuticals. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective National Reimbursement List, 7 are included in the Essential Drug List of China. Tianyin has a pipeline of 10 products pending SFDA approval targeting high incidence indications in China. Tianyin has an extensive nationwide distribution network with 730 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact: James Jiayuan Tong M.D. Ph.D. Chief Financial Officer, Chief Business & Development Officer Director Tianyin Pharmaceutical Co., Inc. Web: http://www.tianyinpharma.com Email: Dr.Tong@tianyinpharma.com Tel: +86-28-8551-6696 (Chengdu, China) +1-949-350-6999 (U.S.) +86 134 36 550011 (China) Address: 23rd Floor Unionsun Yangkuo Plaza No 2 Block 3 South Renmin Road Chengdu, 610041 China Consolidated Balance Sheets June 30, June 30, 2010 2009 Assets Current assets: Cash and cash equivalents $27,009,066 $12,352,223 Accounts receivable, net of allowance for doubtful accounts of $421,079 and $171,947 at June 30, 2010 and
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Tianyin Corporate Presentation Updated
2. Tianyin Reports Record Third Quarter 2010 Financial Results
3. Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16
4. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
5. Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
9. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
10. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... CO (PRWEB) August 27, 2014 Flagship ... analysis services to the pharmaceutical and medical device ... expansion. The fast growing company has consolidated its ... Aurora and Boulder to Westminster, CO, just north of ... Histology Lab, 7575 W. 103rd Ave., Suite 100, Westminster, ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, ... delivery technologies, today announced that it has been selected ... & Industry Association,s 2014 Awards for Excellence ... by an independent panel of judges from SCORE (Counselors ... Award winners will be honored at a gala event ...
(Date:8/27/2014)... 2014 According to the 2013 Raw ... the look and feel of markets for raw materials ... ingredients will push for more branded, science-backed products.” , ... strong market growth in the last decade as consumers ... and cosmetics to fit a more ‘wellness’ lifestyle approach. ...
(Date:8/26/2014)... Scientists have developed what they believe is the ... made in sheets only three atoms thick. , ... two of these single-layer semiconductor materials can be ... a heterojunction. This result could be the basis ... diodes, or LEDs, and solar technologies. , "Heterojunctions ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2
... SUNNYVALE, Calif., Nov. 13 Voler,( http://www.volersystems.com ) ... design capabilities beyond prototypes and custom test,systems to ... human use.,"Voler continues to invest in upgrades to ... our multidisciplinary team," stated Walt Maclay,president of Voler. ...
... Future Healthcare and Education, OLDSMAR, Fla., Nov. ... largest and most established private,cord blood banks and ... agreement as an exclusive retailer with Upromise(R) the,largest ... Since,2004, Cryo-Cell has been the only cord blood ...
... Requires Only Weekly Dosing, SAN DIEGO, Nov. ... trial data demonstrating that ARX201, the company,s,long-acting human ... Serono, normalized insulin-like growth factor I (IGF-I) levels,while ... adults,with Growth Hormone deficiency. The results of this ...
Cached Biology Technology:Voler Expands Medical Device Design Capabilities 2Voler Expands Medical Device Design Capabilities 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 2Cryo-Cell Renews Upromise Industry-Exclusive Agreement 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 4Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated 2Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated 3
(Date:8/27/2014)... Gamblers are greedy bird-brains, University of Warwick research finds ... when they make risky decisions, new research has shown. ... University of Warwick,s Department of Psychology, conducted tests that ... more likely to gamble for high-value than low-value rewards. ... argue that the test results show the important role ...
(Date:8/26/2014)... have developed algorithms to identify weak spots in tendons, ... technology, which needs to be refined before it is ... strains and tiny injuries in the body,s tissues long ... online Aug. 27 in the Journal of the ... nexus of the physical and life sciences. , "Tendons ...
(Date:8/26/2014)... the University of Warwick have provided the first ... protein is linked to early signs of dementia. ... research found that the absence of the protein ... in the nervous system. These changes were shown ... of dementia, including restricted learning and memory formation ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2
... FRANCISCOSatellite observations have revealed the first direct evidence of ... sheet, tarnishing the ice with soot and making it ... the American Geophysical Union meeting this week, an Ohio ... and Infrared Pathfinder Satellite Observation (CALIPSO) satellite, which captured ...
... most powerful X-ray laser, has revealed the three dimensional structure ... causes African trypanosomiasis (or sleeping sickness) in humans. ... cathepsin B enzyme, it will be possible to design new ... causes sleeping sickness, leaving the infected human unharmed. The ...
... recent University of Colorado Cancer Center review in the journal ... promising cancer prevention properties. Meanwhile, an ongoing clinical trial is ... of colon cancer. "While I have been trained ... to deliver bioactive, cancer fighting compounds with food, and this ...
Cached Biology News:Fire and ice: Wildfires darkening Greenland snowpack, increasing melting 2X-ray laser helps slay parasite that causes sleeping sickness 2Clinical trial tests rice bran to prevent cancer 2
... This goat anti-rabbit IgG FITC ... antibody' for immunofluorescent staining on tissues ... antibody is generated in rabbits. It ... controls, such as omitting the primary ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Request Info...
HAS1 (C-14)...
Biology Products: